Search
EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma
EHA and ESMO agreed to collaborate in the production of European Guidelines for different hematological malignancies. For the second workshop in the series participants joined us for the EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma.
Read moreFirst randomized evidence for kinase inhibitor activity in acute myeloid leukemia
Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).
Read moreFrom bedside to Brussels: hematology at the forefront of EU health policy
Access is at the heart of EHA's European Affairs work. More specifically, equitable and affordable access to innovative therapies that are of clear added benefit from a clinical, patient, and public health perspective.
Read moreEHA Research Conference 2025
Dates: March 17-20, 2025
Location: Málaga, Spain
Chairs: Alba Maiques Diaz, Ruud Delwel, Panagiotis Ntziachristos, Marcus Buschbeck, Mark Dawson,
Özgen Deniz, Kimberly Stegmaier, and Nina Cabezas Wallscheid
Registration is now open
EHA is proud to announce the third edition of the EHA Research Conference, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis".…
EHA Research Conference 2024
Dates: March 18-21, 2024
Location: Borovets, Bulgaria
Chairs: Anna Kabanova, Martina Muckenthaler, Andreas Trumpp, Simon Haas, Jean-Emmanuel Sarry, Achille Iolascon, Britta Will and Brian Huntly
Registration is closed
EHA is proud to announce the second edition of the EHA Research Conference, titled "Molecular vulnerabilities and…
GAPP Joint Action
Joint Actions are projects designed and financed by Member State Authorities and the EU to address specific priorities under the EU Health Program.
Read moreA new targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukemia
Patients with chronic lymphocytic leukemia (CLL) that has recurred or isn’t responding to standard treatment need new therapies. A new combination of two targeted therapies is showing potential to eliminate CLL in these circumstances.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- »